ecancermedicalscience

Clinical Study

Repurposing drugs in oncology (ReDO)—Cimetidine as an anti-cancer agent

26 Nov 2014
Pan Pantziarka, Gauthier Bouche, Lydie Meheus, Vidula Sukhatme, Vikas P Sukhatme

Cimetidine, the first H2 receptor antagonist in widespread clinical use, has anti-cancer properties that have been elucidated in a broad range of pre-clinical and clinical studies for a number of different cancer types. These data are summarised and discussed in relation to a number of distinct mechanisms of action. Based on the evidence presented, it is proposed that cimetidine would synergise with a range of other drugs, including existing chemotherapeutics, and that further exploration of the potential of cimetidine as an anti-cancer therapeutic is warranted. Furthermore, there is compelling evidence that cimetidine administration during the peri-operative period may provide a survival benefit in some cancers. A number of possible combinations with other drugs are discussed in the supplementary material accompanying this paper.

Related Articles

Badira Cheriyalinkal Parambil, Nirmalya Roy Moulik, Venkata Rama Mohan Gollamudi, Shyam Srinivasan, Chetan Dhamne, Akanksha Chichra, Gaurav Narula, Mukta Ramadwar, Sumeet Gujral, Tanuja Shet, Epari Sridhar, Poonam Panjwani, Uma Sakhadeo, Siddhartha Laskar, Nehal Khanna, Jifmi Jose Manjali, Sajid Qureshi, Vasundhara Patil, Akshay Baheti, Sneha Shah, Kunal Gala, Pappagudi Subramanian, Prashant Tembhare, Nikhil Patkar, Gaurav Chatterjee, Sweta Rajpal, Dhanlaxmi Shetty, Maya Prasad, Girish Chinnaswamy
Olatunde Olaniyi Abiodun Oluwafemi, Eberechukwu Uchime Kasiemobi, Mustapha Babatunde, Bankole Kofi Adedeji, Oyelayo Oluwaseun Olaoluwa, Ismaheel Aderogba Azeez, Ezekpo Okechukwu Obumneme
Chase Peng Yun Ng, Moira Hegyi, Grant Lewison, Tania Pastrana, Eve Namisango, James Cleary, Barbara Hasties, Eric Kabisa, Helena Musau, Kathryn Spangenberg, Paola Ruiz, Zipporah Ali, Mertixell Mallafre-Larrosa, Alfredo Polo, Julie Torode, Ajay Aggarwal, Richard Sullivan, Mevhibe Hocaoglu